Skip to main content
Shop Plans Learn more about our coverage options including health, Medicare, dental and vision options for you, your family or your employees. Get Started Individual & Family Medicare Employer Vision Dental International Travel Find Care FAQ Blog Members Stay on top of your health care with helpful member resources. Members Home Medicare Health Dental Vision Find Care Member Knowledge Center Member Forms Medicare Forms Library Make a Payment Federal Employees Student Blue Healthy Blue Providers Access tools, policies and the latest information to help you care for our members. Providers Home Network Participation Networks & Programs Claims, Appeals & Inquiries Prior Authorization Services & CPT codes Prescription Drug Search Policies, Guidelines & Codes Provider News Provider FAQ Contact Us Employers Learn about our coverage options for small and large employers, and access tools and resources for your group. Employers Home Shop Employer Plans Employer Portal Support Member Forms & Resources Find Care Blog Agents Access the tools you need: rate quotes, applications, forms, the latest industry news, marketing materials and more. Agents Home Agent Services Check Eligibility Find Care Member Forms & Resources Medicare Forms Library
Contact Us
Log In
I am ... Please select A member A provider An employer An agent
Log in to Agent Services
Log in to Employer Services Register for Employer Services I'm registered but need portal access
Username Forgot username? Continue to Log In Register for Blue Connect Need help? Learn how to log in.
Log in to Blue e Register for Blue e Log in to Dental Blue
Back
Preferred Infliximab Products for Treatment of Autoimmune Disorders June 07, 2021 Pharmacy Medical Policy & Clinical Guidelines Products & Programs

Effective July 1, 2021, Blue Cross and Blue Shield of North Carolina (Blue Cross NC) will be adding two infliximab biosimilars, Avsola and Inflectra, as preferred products for the treatment of autoimmune disorders in addition to our current preferred product, Remicade. Avsola and Inflectra will now be options to use in addition to Remicade. The addition of Avsola and Inflectra as preferred products will give providers more options to choose from along with the ability to use a biosimilar in the place of the brand name Remicade product.  

There is no negative impact to members or providers as our current preferred product Remicade will remain preferred along with Inflectra and Avsola. 

Actions Required Due to These Changes 

Providers with members on impacted drugs should utilize these preferred products before using non-preferred products. Any members who are currently using a non-preferred biosimilar drug should be moved to our preferred products as soon as possible. 

These changes apply to the following lines of business: Administrative Services Only (ASO), fully insured membership, Blue Card IPP Host and the State Health Plan (SHP).